PEPG stock has a bullish outlook, with HC Wainwright maintaining a "Strong Buy" rating and raising the price target to $26, citing confidence in the company's clinical progress and pipeline potential. Despite recent challenges, including FDA clinical holds, analysts like Andrew Fein emphasize the long-term viability of PepGen's treatments, particularly in addressing Duchenne muscular dystrophy. The current price offers significant upside potential if the company successfully resolves regulatory concerns and advances its trials.